Kymera Therapeutics outlines 2026 clinical trial plans
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
January 13, 2026 7:00 AM ESTKT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027
KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027
KT-579 Phase 1 HV clinical trial expected to start in 1Q26, with data expected in 2H26
Advancing at least one new development candidate towards IND for a first-in-class, oral immunology program in 2026
Well-capitalized with $1.6 billion1 in cash and runway into 2029
Kymera to present its 2026 objectives at the... More
